tiprankstipranks
Trending News
More News >
Clinigence Holdings (NUTX)
NASDAQ:NUTX
US Market

Clinigence Holdings (NUTX) AI Stock Analysis

Compare
220 Followers

Top Page

NU

Clinigence Holdings

(NASDAQ:NUTX)

75Outperform
Nutex Health Inc. has demonstrated strong financial growth and improved profitability, highlighted by a significant increase in revenue and net income. The stock exhibits strong technical momentum, trading well above key moving averages, indicating a bullish trend. While the company is reasonably valued, the lack of a dividend yield may be a minor detraction for some investors. The earnings call further supports the positive outlook, with successful debt management and strategic expansion initiatives. However, high leverage and operational challenges related to the No Surprises Act could pose risks moving forward.
Positive Factors
Business Expansion
The company opened four new facilities in 2024, expanding its network to 24 micro-hospitals, demonstrating its growth and expansion strategy.
Financial Performance
Nutex Health Inc holds a strong cash position with cash significantly exceeding long-term debt.
Negative Factors
Market Valuation
Shares currently trade at an EV/revenue multiple of 0.4x our 2025 estimate, below the peer average of 1.6x, excluding NUTX.
Valuation Concerns
Shares currently trade at a discount to peers, reflecting the early stage and unproven nature of Nutex's business model.

Clinigence Holdings (NUTX) vs. S&P 500 (SPY)

Clinigence Holdings Business Overview & Revenue Model

Company DescriptionNutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments. This division owns and operates 21 facilities in 8 states. The Population Health Management division owns and operates provider networks, such as independent physician associations. Its management services organizations provide management, administrative, and other support services to its affiliated hospitals and physician groups. This division's cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, as well as allows to deliver care. The company is based in Houston, Texas.
How the Company Makes MoneyClinigence Holdings makes money primarily through the sale of its technology solutions to healthcare providers and organizations. The company's revenue model includes subscription-based fees for its software platforms, which offer analytics and population health management tools. Additionally, Clinigence may generate income through consulting services and partnerships with healthcare providers who seek to implement value-based care initiatives. These revenue streams are supported by the company's ability to deliver actionable insights and data-driven strategies that help healthcare organizations improve efficiency and patient outcomes.

Clinigence Holdings Financial Statement Overview

Summary
Clinigence Holdings has shown strong revenue growth and improved profitability with significant increases in total revenue and net income. However, high leverage and fluctuating EBIT and EBITDA margins pose financial risks. The company's cash flow position has improved with positive free cash flow, indicating better financial health.
Income Statement
65
Positive
The company's revenue has shown significant growth from 2019 to 2024, with a notable increase in Total Revenue in 2024 to $479.9 billion. Gross Profit Margin and Net Profit Margin have improved significantly from negative figures in 2023 to strong positive values in 2024, indicating improved operational efficiency and profitability. However, the EBIT and EBITDA margins have fluctuated, suggesting some instability in operational performance over the years.
Balance Sheet
58
Neutral
The Debt-to-Equity Ratio is relatively high, indicating significant leverage, which could pose financial risks. Despite this, the company has a strong equity base with a Stockholders' Equity of $201.9 billion in 2024. The Equity Ratio has improved over the years, suggesting better asset financing through equity rather than debt.
Cash Flow
72
Positive
Operating Cash Flow has been consistently positive, showing strong cash-generating capability. The Free Cash Flow turned positive in 2024, signaling an improvement in financial health. However, the Free Cash Flow Growth Rate fluctuated significantly in previous years, pointing to potential volatility in cash flow management.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
479.95M247.65M219.29M331.53M273.42M
Gross Profit
196.26M34.77M13.45M179.28M271.60M
EBIT
130.62M-31.77M-5.14M170.26M152.33M
EBITDA
148.65M-14.58M-393.96M183.45M-5.12M
Net Income Common Stockholders
52.18M-45.79M-432.74M132.59M105.97M
Balance SheetCash, Cash Equivalents and Short-Term Investments
43.58B22.00M34.26M36.12M25.51M
Total Assets
655.32B398.25M431.75M394.65M308.55M
Total Debt
314.28B275.76M267.20M178.55M150.12M
Net Debt
270.70B253.75M232.95M142.43M124.61M
Total Liabilities
453.43B319.14M311.42M203.07M161.19M
Stockholders Equity
201.89B61.45M95.86M114.65M85.81M
Cash FlowFree Cash Flow
23.15B-8.24M35.97M136.51M20.07M
Operating Cash Flow
23.15B1.26M50.61M173.43M81.26M
Investing Cash Flow
-2.67B-11.24M-4.34M-36.98M-61.19M
Financing Cash Flow
1.09M-2.27M-48.13M-125.85M-2.56M

Clinigence Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price140.51
Price Trends
50DMA
74.50
Positive
100DMA
56.44
Positive
200DMA
37.89
Positive
Market Momentum
MACD
23.52
Negative
RSI
75.48
Negative
STOCH
82.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Positive. The current price of 140.51 is above the 20-day moving average (MA) of 104.31, above the 50-day MA of 74.50, and above the 200-day MA of 37.89, indicating a bullish trend. The MACD of 23.52 indicates Negative momentum. The RSI at 75.48 is Negative, neither overbought nor oversold. The STOCH value of 82.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUTX.

Clinigence Holdings Risk Analysis

Clinigence Holdings disclosed 62 risk factors in its most recent earnings report. Clinigence Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Clinigence Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$807.15M15.6450.22%93.80%
60
Neutral
$273.80M-36.07%-7.93%
51
Neutral
$5.31B3.33-39.82%2.92%17.95%1.84%
IVIVA
50
Neutral
$334.88M344.74%-47.32%-26.67%
48
Neutral
$306.56M-79.69%-33.43%8.94%
46
Neutral
$338.93M-39.07%0.42%
33
Underperform
$236.18M-139.56%-33.79%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NUTX
Clinigence Holdings
140.51
133.98
2051.76%
ATYR
aTyr Pharma
3.45
1.85
115.63%
IVA
Inventiva
3.77
0.61
19.30%
CMPX
Compass Therapeutics
2.12
0.64
43.24%
OLMA
Olema Pharmaceuticals
5.10
-4.73
-48.12%
CADL
Candel Therapeutics
5.00
-1.43
-22.24%

Clinigence Holdings Earnings Call Summary

Earnings Call Date: Mar 31, 2025 | % Change Since: 198.77% | Next Earnings Date: May 19, 2025
Earnings Call Sentiment Positive
The call highlighted strong financial growth, successful arbitration outcomes, and effective debt management, despite challenges posed by the No Surprises Act and the operational burden of the arbitration process.
Highlights
Exceptional Revenue Growth
For the full year of 2024, total revenue reached $479.9 million, up 94% from $247.6 million in 2023.
Significant EBITDA Increase
Adjusted EBITDA increased from $10.8 million in 2023 to $123.7 million in 2024, up over 1,000%.
Net Income Turnaround
Full year 2024 net income was $52 million compared to a loss of $46 million in 2023.
Hospital Expansion
Opened four new hospitals in 2024, bringing the total to 24 hospitals across 11 states.
Debt Management
Long-term debt decreased from $26 million in 2023 to $22 million in 2024, emphasizing fiscal responsibility.
Arbitration Process Success
Achieved an 80% win rate in arbitration, resulting in significant revenue recovery, with a 150% to 250% increase in reimbursement on the facility collection side.
Lowlights
Impact of No Surprises Act
The flawed implementation of the No Surprises Act and its arbitration process has hit revenue per patient reimbursement hard, with insurer payments for emergency services dropping roughly 30% in 2022.
Arbitration Process Challenges
The arbitration process is costly, labor-intensive, and time-consuming, posing a significant operational challenge.
Company Guidance
During the Nutex Health Fourth Quarter 2024 Earnings Call, significant financial metrics were highlighted, demonstrating the company's robust performance. Total revenue for the full year reached $479.9 million, marking a 94% increase from 2023's $247.6 million. The adjusted EBITDA saw an impressive surge from $10.8 million in 2023 to $123.7 million in 2024, reflecting a growth of over 1,000%. Net income also improved, reaching $52 million in 2024, compared to a loss of $46 million the previous year. Patient volume rose by 17%, with total hospital visits increasing from 144,000 in 2023 to 168,000 in 2024, driven by a 6.5% growth from mature hospitals. Despite opening four new hospitals, long-term debt was efficiently managed, increasing only slightly in the current portion from $10.8 million in 2023 to $14 million in 2024, while net long-term debt decreased from $26 million to $22 million. These metrics underscore Nutex Health's successful expansion strategy and fiscal discipline amidst challenges like the No Surprises Act and its arbitration process.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.